Beta Bionics, Inc. (BBNX)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below the required floor of 3) and the shadow sum-gate flag is false, so no bullish entry — including no SHADOW_FST9 paper plan — can be taken; the chart independently scores 2/5 with price under every short/intermediate MA, MACD negative and expanding, and five consecutive down sessions.
Company overview
Beta Bionics, Inc. is a medical technology company focused on developing automated insulin delivery systems for diabetes management. Its flagship product, the iLet Bionic Pancreas, is designed for type 1 diabetes treatment, with additional innovations in development for broader diabetes care. The company collaborates with Xeris Pharmaceuticals and Abbott Diabetes Care to enhance its product offerings.
Fundamental
fairBeta Bionics shows strong revenue growth and a solid balance sheet, but faces widening losses and regulatory challenges.
Mixed, high-risk growth story: revenue up roughly 40% with gross margin near 59% and a debt-free balance sheet holding $373.6M of cash and Treasuries, but the company still burns $17-19M of adjusted EBITDA per quarter, DME-channel iLet sales are declining, and an open FDA Warning Letter, four recalls, a 522 post-market order and a securities class action keep the risk profile elevated. Watchlist rather than a clean buy.
Sentiment
weakMedia sentiment has cooled, and unresolved safety and litigation issues persist.
Determinate cooling in media sentiment (+0.31 in the 2026-08-05 to 2026-10-04 baseline vs +0.03 in the 2026-10-20 to 2026-11-03 scoring window) after a Q3 print that beat on revenue but carried a narrowed, timing-shifted FY2026 guidance range, with no market-rewarded bullish element — the only bullish leg is a routine analyst target raise, which does not clear the rewarded-bullish bar. The Red-Flag Screen fired no severe flag (legal_analyze_investigation regulator_confirmed_count of 0 with every item law-firm marketing; no going-concern, auditor-change or refinancing trigger, and a lawful raise by a healthy balance sheet), so no cap ceiling is doing the work here — the weak-sentiment read is explicit, resting on the determinate cooling delta plus an unresolved iLet safety/litigation overhang.
Technical
weakThe stock is in a bearish trend with no reversal confirmation, limiting technical entry opportunities.
Trend frame: price 15.10 sits below sma20 17.79, sma50 18.95, ema9 17.27, ema21 17.96, wma9 17.33, wma21 17.77, dema14 16.92, tema14 16.49 and today's VWAP 15.37 — a fully bearish short/intermediate stack — while still holding above sma200 14.79, so the primary uptrend is not yet broken. Momentum: rsi14 35.72 and falling (not yet under 30), Williams %R -97.96 deeply oversold, macdLine -0.57 below macdSignal -0.27 with macdHistogram -0.30 expanding negative, adx14 17.65 (weak trend strength, though ticking up from 17.29 as the slide extends). Volatility: atr14 1.43 = 9.47% of price, stdDev20 1.44 — a high-volatility name. Volume: avgDollarVolume20 $20.60M with the last three regular sessions at roughly $18.3M / $13.3M / $10.8M, distribution-heavy on the decline. Chart quality scores 2/5 (weak bearish, bounce-only): the deep oversold reading plus the SMA200 shelf at 14.79 could produce a reflex bounce, but there is no trend or momentum confirmation of a bottom, so no technical long setup exists. Independently of the chart, qualitativeScore 2 (< 3) hard-blocks any bullish action under the qualitative override gate, so the verdict is Do Nothing.
You’re looking at 2026-11-03 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

